

FIG. 1A

Variable heavy chain sequences of humanized variants of Antibody 309

309 VK	EVQLVESGGGLVQPGQSLRLTQVQSGDQSRGSGVDVFGPGGGLMADKATKQ	ELKSLISISDTSKQVPLKMNLAERATLAFCA	ESIAADIPED	EQFTMTQTS
309VK1-13*01	EVQLVESGGSLVQPGGSLRLSAAQSFSLNSGVV	EVKQATKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309VK3-53*01	EVQLVESGGSLVQPGGSLRLSCAAQSFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309VK3-66*04	EVQLVESGGSLVQPGGSLRLSCAAQSFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309VK8-34*01	EVQLVQSGAGLKPSETTSLTCAVTFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309VK8-34*01	EVQLVQSGAGLKPSETTSLTCAVTFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309VK1-59*01	EVQLVQSGAGLKPSETTSLTCAVTFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309VK8-34*01V71R	EVQLVQSGAGLKPSETTSLTCAVTFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309VK8-59*01V71R	EVQLVQSGAGLKPSETTSLTCAVTFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309VK1-02*01	EVQLVQSGAGLKPSETTSLTCAVTFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309VK1-03*01	EVQLVQSGAGLKPSETTSLTCAVTFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309-1QRYHR71	EVQLVQSGAGLKPSETTSLTCAVTFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED
309-1QRYHR71	EVQLVQSGAGLKPSETTSLTCAVTFSLNSGVV	EVKQAFKSGLENVYVINGNNTYIN	INTEGSEFTISRNKASLILOMELRAGDAVYICAR	ACGRVDPED

FIG. 1B

Variable light chain sequences of humanized variants of Antibody 309

309 VK	DIQMTQSPSSLSASVGDRVTITCAEQNIIVYLD	YVQKLSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309VK1-13*01	DIQMTQSPSSVLSASVGDRVTITCAEQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309VK1-17*01	DIQMTQSPSSLSASVGDRVTITCAEQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309VK1-6*01	AIQMTQSPSSLSASVGDRVTITCAEQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309VK3-11*02	EVILTQSPATLSLSGGERATLSKASQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309VK1-12*01Y87F	DIQMTQSPSSVLSASVGDRVTITCAEQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309VK1-17*01Y87F	DIQMTQSPSSLSASVGDRVTITCAEQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309VK1-6*01Y87F	AIQMTQSPSSLSASVGDRVTITCAEQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309VK3-11*02Y87F	EVILTQSPATLSLSGGERATLSKASQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309-1Q6YK	EVILTQSPATLSLSGGERATLSKASQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK
309-1Q6YK	EVILTQSPATLSLSGGERATLSKASQNIIVYLD	YVQKPSGAPKLLI	VTNSLHT	IFSRFSGSGGSDFTLTISLSLQEDFAVYICQNSGWT	FGGTALEIK

Anti-PAR-2 antibodies inhibiting trypsin in the PAR-2 calcium flux cell assay




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D







FIG. 3E












FIG. 7C








FIG. 9B




FIG. 9D




FIG. 9A




FIG. 9C




FIG. 10A

FIG. 10B

FIG. 10C

FIG. 10D




FIG. 10F




FIG. 10H




FIG. 10E




FIG. 10G